FEATURES OF EXCRETION OF MELATONIN IN URINE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND NON-ALCOHOLIC FATTY LIVER DISEASE WITH MANIFESTATIONS OF FIBROSIS AND ITS RELATIONSHIP WITH CERTAIN METABOLIC AND IMMUNOLOGICAL INDICATORS.

To study the features of secretion of melatonin in the urine in patients with DM type 2 and NAFLD with manifestations of fibrosis and its relationship with some metabolic and immunological parameters, 23 patients with DM type 2 and NAFLD were examined. The degree of fibrosis in patients was diagnosed on the basis of static elastography and the study of indirect fibrosis markers 16 persons (72%) diagnosed with mild fibrosis (F0-F1 on METAVIR), 5 people (18.2%) - with moderate fibrosis (F2-F3 on METAVIR). Only 2 (8.7%) patients did not have any fibrotic disorders, so they were excluded from the further study. All patients underwent determination of melatonin excretion of albumin and in daily urine, as well as the determination of homocysteine in the blood. The level of excretion of melatonin in the urine in patients with DM type 2 and NAFLD did not depend on the degree of fibrosis and on the average was 89.50±16.66 mmol/day, which exceeded the reference values. It has been established that the increase in melatonin level in patients with DM type 2 and NAFLD is associated with the presence of fibrotic changes in the liver and a decrease in the activity of the inflammatory process. In addition, a direct correlation was found between the excretion of melatonin and homocysteine (r=0.43), as well as between melatonin and albumin excretion in the urine (r=0.20). Thus, an increased level of excretion of melatonin in the urine can be not only a marker of liver fibrosis, but also a predictor of cardiovascular disorders in patients with DM type 2 and NAFLD.

[The distribution of HLA-system antigens in lung cancer patients]. / Raspredelenie antigenov sistemy HLA u bol'nykh rakom legkikh.

Data on 152 cases of lung cancer were studied in an attempt to identify relationship between immunogenetic markers of the HLA system, on the one hand, and histologic pattern of the disease and effectiveness of radiation treatment, on the other. Control group included 200 healthy blood donors. Eight A locus antigens and 16 B locus antigens were studied. In the entire group of patients, HLA-Aw19 antigen was observed less frequently as compared to controls. Similarly infrequent were haplotypes containing the antigen. The occurrence of HLA-B16 antigen was higher in the adenocarcinoma group. Resistance to treatment, particularly, in patients with small-cell histology was associated with the presence of HLA-B8 antigen. Possibility of tissue typing of antigens for diagnosis and prediction of response in lung cancer patients is discussed.